DZD9008 is the first original Chinese Class I drug targeting EGFR ex20ins in advanced NSCLC with lower affinity for EGFR wild-type (70) because of its molecular structure containing an acrylamide moiety and an amino-pyrimidine parent ring. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.